The Great Convergence: 2026 - From Science Projects to Scale
Radiopharma, ADCs and cell and gene therapy have stopped operating as separate fields. They are now competing over the same tumour targets while the supply chains that deliver them harden at the same time. This briefing sets out where those collisions fall in 2026, and why supply chain and staffing decide the outcome rather than biology.
What this report answers
- Where are next-generation ADCs and targeted alpha therapies now competing for the same tumour target?
- What decides whether a target calls for a biological answer or a physics-based one?
- How much commercial alpha-emitter capacity actually comes online in 2026, and who is building it?
- Why are two different alpha supply chain architectures emerging, and what does each demand operationally?
- What is forcing cell and gene therapy out of the ex vivo model, and what replaces it?
- Why has the cost of capital changed what acquirers will pay for a discovery platform?
50-100 Ci
the annual commercial alpha-emitter capacity the briefing projects for 2026, a step change from the legacy stockpile supply that had capped the sector.
$300bn
the revenue the briefing attributes to loss of exclusivity across big pharma between 2025 and 2030, which is what makes near-term revenue replacement the dominant acquisition logic.
What the analysis establishes
The collision zones
The briefing maps the tumour antigens where next-generation ADCs and targeted alpha therapies now compete head to head, having moved past the saturated targets of the last cycle. For each contested target it names the competing assets, the sponsors behind them and the mechanistic argument each side makes. The framing is modality selection rather than target validation: what property of the tumour decides which approach should win.
Bystander effects and the hybrid modality
A short technical section separates the chemical bystander effect ADCs depend on from the radiological one alpha emitters produce, gives the range over which the second operates, and explains why that matters in tumours where antigen expression is uneven or resistance pumps are active. It then covers the hybrid class that conjugates an isotope to an antibody, the pharmacokinetic problem it solves, and the half-life it is designed around.
The alpha supply chain moves from scarcity to scale
The briefing quantifies the step change in commercial alpha-emitter capacity arriving in 2026 against the legacy government-stockpile supply that capped the sector for years. It names the production routes and the facilities behind the increase, across the United States, Belgium and France, and gives the regulatory filing or commissioning milestone each site is working toward, dated to the quarter, so a reader can track whether the capacity lands.
Two architectures, two operating models
A central divergence in the report is between a centralised manufacturing model built around a longer-lived isotope and a generator-based model built around a much shorter one. The briefing gives both half-lives, sets out what each one forces on the distribution network that carries it, identifies which sponsors have committed to which architecture, and shows how siting a facility becomes a decay-management decision rather than a property one.
The in vivo pivot and the workforce it needs
The cell and gene therapy section establishes why the ex vivo model has hit a commercial ceiling, using cost of goods and manufacturing failure rates, then describes the two technical routes competing to replace it and who is pursuing each. It sets out the staffing constraint underneath all of it: a hybrid skill set spanning aseptic biologics and nuclear regulation, and what that scarcity is doing to pay.
The Great Recalibration
The investment section works from a stabilised cost of capital and a quantified patent cliff to explain why long-dated platform cash flows are being discounted so heavily, and what that does to the kind of company acquirers will now pay a premium for. It closes with a stated position on what to overweight and what to avoid across radiopharma, ADCs and cell and gene therapy going into 2026.
How it was built
Written as a forward view from a December 2025 planning horizon rather than a retrospective. It blends public sources - clinical trial registries, corporate filings, company disclosures, deal activity and regulatory updates - with hiring signals and market observations gathered through ProGen Search's own work across radiopharma, ADCs, biologics and cell and gene therapy. Compensation points come from 2026 salary data on roles the firm recruits directly. The report is explicit that its capacity forecasts, valuation sensitivities and clinical projections are modelled scenarios rather than guaranteed outcomes, and that figures varying by site, geography or programme design are shown as ranges or directional estimates instead of single numbers. Trials are cited by registry identifier and readouts are dated to the half or the quarter, so the reasoning can be tested against events as they land rather than taken on trust.
Written for hiring managers, investors and operators in radiopharma, ADCs and cell and gene therapy who are making capacity, partner-selection and organisational design decisions for 2026.
Contents
- The 2026 Mandate: Physics, Logistics, and the End of the Platform Premium
- Executive Summary: The Great Convergence
- The Clinical Battlefield (Radiopharma vs ADCs)
- The Supply Chain Moat (The Alpha Revolution)
- The In Vivo Pivot and Workforce Crisis
- The Investment Verdict (The Great Recalibration)
- Conclusion: The New Industrial Logic
Organisations covered
AstraZeneca, Bristol Myers Squibb, Capstan Therapeutics, Daiichi Sankyo, Eli Lilly, Fusion Pharmaceuticals, Interius, Kelonia Therapeutics, Mariana Oncology, NorthStar Medical, Novartis, Nucleus RadioPharma, Orano Med, Orna, PanTera, PeptiDream, Point Biopharma, RayzeBio, Sanofi, Umoja Biopharma
The full 7-page briefing is free. Tell us where to send it and it downloads immediately.